Skip to content

For Every 3 People with Diabetes, 1 Faces Kidney Disease

We identify that 1, over a decade in advance, paving a path to prevention. 

Diabetes-related kidney disease (DKD) is a condition that remains silent and asymptomatic, until suddenly, it's not. We're on a mission to change that trajectory. Our solution provides up to 12 years of advance detection, paving the way for early interventions that can delay or prevent the disease's progression.

img-compass-desktop

Compass™

A Digital Hub for Intelligent Care

Compass isn't just a digital platform; it's the intelligence that drives our insights. Powered by AI, Compass transforms intricate laboratory data into concise risk reports and personalized, actionable treatment plans. Compass also serves as a central hub for both providers and patients, streamlining order and account management.

img-compass-desktop
img-navidkd-kits-1

NaviDKD®

A powerful predictive Screening

NaviDKD is a precise and clinically-validated screening kit for DKD risk assessment. With just a standard 2ml blood draw, our CLIA-certified lab takes care of sample processing and risk analysis. Seamlessly integrated with Compass, NaviDKD delivers more than lab results—it provides clear risk stratification and personalized treatment plans.

icon-magnifying-glass

EARLIEST DETECTION

Uncover DKD with the most advanced warning available.

icon-stopwatch

EARLy intervention

Take timely measures to delay or prevent the progression of DKD, reducing the need for invasive treatments.

icon-heart

improved health

Pave the way to better health and quality of life through proactive and preventive care.

icon-heart

ECONOMIC IMPACT

Drive cost savings by preventing costly complications and reducing healthcare expenditures.

Why It Matters

One in three individuals with diabetes will face kidney disease, a condition affecting over 12 million Americans and burdening our healthcare system with nearly $28 billion annually. The challenge? Most cases are diagnosed at Stage 3a or later when slowing its progression becomes increasingly difficult. Early detection of at-risk patients can pave the way for targeted interventions to delay or even prevent DKD. This proactive approach doesn't just elevate patient outcomes—it also offers a potential to cut healthcare expenses by approximately $8 billion.

img-why-it-matters

Start Your Journey

Our solutions empower health systems, insurance companies, providers, and patients with powerful tools to stay ahead of health complications. Get in touch and discover how Journey Biosciences can help you or your organization make a meaningful impact today.